PRIMARY STUDY
The efficacy of an association of palmitoylethanolamide and alpha-lipoic acid in patients with chronic prostatitis/chronic pelvic pain syndrome: A randomized clinical trial
Key Findings: In subjects with chronic prostatitis/chronic pelvic pain treatment with Palmitoylethanolamide plus Alpha-lipoic acid significantly reduced NIH-CPSI score.
Type of Study: Clinical Trial
Study Sample Size: 44
Study Result: Positive
Research Location(s): Italy
Year of Pub: 2017
Cannabinoids Studied: Palmitoylethanolamide (PEA)
Phytocannabinoid Source: Unspecified
DOSING DETAILS 
Study Dosing Objective: Effective Dose, Safety Profile
Established Protocol: Effective dose
Route of Administration: Oral (Ingestion)
Dosing Regimen: Palmitoylethanolamide (300 mg) Alpha-lipoic acid (300 mg)
Treatment Duration: 12 weeks
Clinical Relevance: Palmitoylethanolamide (PEA) and Alpha-lipoic acid (ALA) shows promising efficacy over Serenoa Repens in patients with CP/CPPS.
Citation: Giammusso B, et al. The efficacy of an association of palmitoylethanolamide and alpha-lipoic acid in patients with chronic prostatitis/chronic pelvic pain syndrome: A randomized clinical trial. Arch Ital Urol Androl. 2017; 89:17-21. doi: 10.4081/aiua.2017.1.17
Authors: Giammusso B, Di Mauro R, Bernardini R
